Evan Seffar, MS

Computational Biologist
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST